Literature DB >> 2720655

Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells.

D V Woo1, D Li, J A Mattis, Z Steplewski.   

Abstract

A monoclonal antibody, 17-1a, which reacts with antigen expressed in human colon cancers was radiolabeled in high specific activity with 125I. The combination of the antibody and this radionuclide was observed to elicit specific cellular damage after being internalized into cells of the SW1116 human colon cancer cell line. The degree of internalization was quantitatively measured and found to increase over time to 49% after a 48-h incubation period. During this period, significant chromosome aberrations were observed in the SW1116 cell line due to the Auger electrons of 125I. This damage was not observed using Na125I, a nonimmunoreactive radiolabeled antibody, or cells which did not contain the requisite antigen. The number of chromosomal aberrations increased with increasing radioactive concentration of 125I-17-1a. The nuclear damage resulted in specific cellular cytotoxicity and decreased cell survival of SW1116 cells exposed to various concentrations of 125I-17-1a.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2720655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Nuclear translocation of monoclonal antibody directed against cell-surface carbohydrate Y determinant.

Authors:  E M Rakowicz-Szulczynska; Z Steplewski; H Koprowski
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

2.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

3.  Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor alpha.

Authors:  K Adachi; P Belser; H Bender; D Li; U Rodeck; E N Benveniste; D Woo; W H Schmiegel; D Herlyn
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

Authors:  Victor W van Beusechem; Jacques Grill; D C Jeroen Mastenbroek; Thomas J Wickham; Peter W Roelvink; Hidde J Haisma; Martine L M Lamfers; Clemens M F Dirven; Herbert M Pinedo; Winald R Gerritsen
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

6.  Breaks in DNA accompany estrogen-receptor-mediated cytotoxicity from 16 alpha[125I]iodo-17 beta-estradiol.

Authors:  M W Beckmann; A Scharl; B J Rosinsky; J A Holt
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells.

Authors:  B J Kroesen; A ter Haar; H Spakman; P Willemse; D T Sleijfer; E G de Vries; N H Mulder; H H Berendsen; P C Limburg; T H The
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

8.  Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma.

Authors:  M A Tempero; Y Haga; C Sivinski; Z Steplewski; H D Kay; P Pour
Journal:  Int J Pancreatol       Date:  1991

Review 9.  Auger electrons for cancer therapy - a review.

Authors:  Anthony Ku; Valerie J Facca; Zhongli Cai; Raymond M Reilly
Journal:  EJNMMI Radiopharm Chem       Date:  2019-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.